Reducing the risk of failure: biomarker-guided trial design

被引：12
|
作者：
Townsend, Michael J. [1 ]
Arron, Joseph R. [2 ]
机构：
[1] Genentech Inc, Biomarker Discovery OMNI, 1 DNA Way, San Francisco, CA 94080 USA
[2] Genentech Inc, Immunol Discovery, 1 DNA Way, San Francisco, CA 94080 USA
来源：
NATURE REVIEWS DRUG DISCOVERY | 2016年 / 15卷 / 08期
关键词：
D O I：
10.1038/nrd.2016.124
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Drug candidates may fail in clinical trials for many reasons. Biomarker-guided clinical trial design can mitigate the risk of failure and enable more informative clinical experiments regardless of outcomes.
引用
收藏
页码：517 / 518
页数：2
相关论文
共 50 条
  • [41] Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes
    Philipp Schuetz
    Beat Mueller
    Intensive Care Medicine, 2014, 40 : 141 - 141
  • [42] Biological and analytical variation of clinical biomarker testing: Implications for biomarker-guided therapy
    Wu A.H.B.
    Current Heart Failure Reports, 2013, 10 (4) : 434 - 440
  • [43] Biomarker-guided neuromodulation aids memory in traumatic brain injury
    Kahana, Michael J.
    Ezzyat, Youssef
    Wanda, Paul A.
    Solomon, Ethan A.
    Adamovich-Zeitlin, Richard
    Lega, Bradley C.
    Jobst, Barbara C.
    Gross, Robert E.
    Ding, Kan
    Diaz-Arrastia, Ramon R.
    BRAIN STIMULATION, 2023, 16 (04) : 1086 - 1093
  • [44] Biomarker-Guided Strategy for Treatment of Autism Spectrum Disorder (ASD)
    Liu, Hua
    Talalay, Paul
    Fahey, Jed W.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2016, 15 (05) : 602 - 613
  • [45] Early, biomarker-guided steroid dosing in COVID-19 Pneumonia: a pilot randomized controlled trial
    Odeyemi, Yewande E.
    Chalmers, Sarah J.
    Barreto, Erin F.
    Jentzer, Jacob C.
    Gajic, Ognjen
    Yadav, Hemang
    CRITICAL CARE, 2022, 26 (01)
  • [46] Are We Ready for Biomarker-Guided Immune Modulation in Critical Care?
    Leligdowicz, Aleksandra
    CRITICAL CARE MEDICINE, 2023, 51 (12) : 1827 - 1829
  • [47] Biomarker-guided antibiotic cessation in sepsis: evidence and future challenges
    Claxton, Andrew N.
    Dark, Paul M.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2018, 79 (03) : 136 - 141
  • [48] Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis
    Dark, Paul
    Hossain, Anower
    Mcauley, Daniel F.
    Brealey, David
    Carlson, Gordon
    Clayton, Jonathan C.
    Felton, Timothy W.
    Ghuman, Belinder K.
    Gordon, Anthony C.
    Hellyer, Thomas P.
    Lone, Nazir I.
    Manazar, Uzma
    Richards, Gillian
    Mccullagh, Iain J.
    Mcmullan, Ronan
    Mcnamee, James J.
    Mcneil, Hannah C.
    Mouncey, Paul R.
    Naisbitt, Micheal J.
    Parker, Robert J.
    Poole, Ruth L.
    Rostron, Anthony J.
    Singer, Mervyn
    Stevenson, Matt D.
    Walsh, Tim S.
    Welters, Ingeborg D.
    Whitehouse, Tony
    Whiteley, Simon
    Wilson, Peter
    Young, Keith K.
    Perkins, Gavin D.
    Lall, Ranjit
    ADAPT Sepsis Collaborators
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024,
  • [49] Biomarker-guided translation of brain imaging into disease pathway models
    Erfan Younesi
    Martin Hofmann-Apitius
    Scientific Reports, 3
  • [50] A biomarker-guided first-in-human trial of subcutaneous ALM201 in patients with solid tumours
    El-Helali, A.
    Plummer, R.
    Jayson, G.
    Coyle, V.
    Rogers, C.
    D'Arcangelo, M.
    Graham, M.
    Drew, Y.
    Clamp, A.
    McCann, J.
    McCavigan, A.
    Knight, L.
    McCabe, N.
    Keating, K.
    Dyer, R.
    Harrison, T.
    Harkin, P.
    Robson, T.
    Kennedy, R.
    Wilson, R.
    ANNALS OF ONCOLOGY, 2016, 27
12345